The Combination Therapy of Fluorouracil and Oxaliplatin Suppress the Progression of Colon Cancer Through miR-183-5p/SOCS3 Axis and Downregulating PD-L1

References

• Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015;33(16):1787–1796. doi:10.1200/JCO.2014.60.021325918287
   PubMed Web of Science ®Google Scholar
• Treasure T, Monson K, Fiorentino F, et al. The CEA Second-Look Trial: a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ Open. 2014;4(5):e004385. doi:10.1136/bmjopen-2013-004385
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Luber B, Siegel N, et al. Immunopathologic stratification of colorectal cancer for checkpoint blockade immunotherapy. Cancer Immunol Res. 2019;7(10):1574–1579. doi:10.1158/2326-6066.CIR-18-092731439614
   PubMed Web of Science ®Google Scholar
• Franke AJ, Skelton WP, Starr JS, et al. Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches. J Natl Cancer Inst. 2019;111(11):1131–1141. doi:10.1093/jnci/djz09331322663
   PubMedGoogle Scholar
• Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396. doi:10.3389/fonc.2019.0039631139574
   PubMed Web of Science ®Google Scholar
• Filippova N, Yang X, An Z, et al. Blocking PD1/PD-L1 interactions together with MLN4924 therapy is a potential strategy for glioma treatment. J Cancer Sci Ther. 2018;10(8):190–197. doi:10.4172/1948-5956.100054330393513
   PubMedGoogle Scholar
• Kythreotou A, Siddique A, Mauri FA, et al. PD-L1. J Clin Pathol. 2018;71(3):189–194. doi:10.1136/jclinpath-2017-20485329097600
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51. doi:10.1158/2159-8290.CD-14-086325358689
   PubMed Web of Science ®Google Scholar
• Gasiulė S, Dreize N, Kaupinis A, et al. Molecular insights into miRNA-driven resistance to 5-fluorouracil and oxaliplatin chemotherapy: miR-23b modulates the epithelial–mesenchymal transition of colorectal cancer cells. J Clin Med. 2019;8(12):2115. doi:10.3390/jcm8122115
   PubMed Web of Science ®Google Scholar
• Liu T, Zhang X, Du L, et al. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer. Mol Cancer. 2019;18(1):43. doi:10.1186/s12943-019-0981-730890168
   PubMed Web of Science ®Google Scholar
• Wang G, Zhou J, Lu F, et al. Downregulation of microRNA‑183‑5p inhibits the proliferation and invasion of colorectal cancer cells by inactivating the reticulocalbin‑2/Wnt/β‑catenin signaling pathway. Mol Med Rep. 2019;19(5):4475–4483. doi:10.3892/mmr.2019.1005930896885
   PubMed Web of Science ®Google Scholar
• Zheng S, Zhong YF, Tan DM, et al. miR-183-5p enhances the radioresistance of colorectal cancer by directly targeting ATG5. J Biosci. 2019;44(4). doi:10.1007/s12038-019-9918-y
   Web of Science ®Google Scholar
• Xu JZ, Shao CC, Wang XJ, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death Dis. 2019;10(3):175. doi:10.1038/s41419-019-1382-y30787278
   PubMed Web of Science ®Google Scholar
• Li M, Zheng R, Yuan FL. MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(18):5987–5993. doi:10.26355/eurrev_201809_1593330280781
   PubMed Web of Science ®Google Scholar
• Hamilton KE, Lund PK, J A G, et al. Suppressor of cytokine signaling 3 (SOCS3) is not an independent biomarker of colorectal adenoma risk. BMC Res Notes. 2010;3:144. doi:10.1186/1756-0500-3-14420500855
   PubMedGoogle Scholar
• Wang J, Guo J, Fan H. MiR-155 regulates the proliferation and apoptosis of pancreatic cancer cells through targeting SOCS3. Eur Rev Med Pharmacol Sci. 2019;23(12):5168–5175. doi:10.26355/eurrev_201906_1818131298410
   PubMed Web of Science ®Google Scholar
• Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 2014;20(7):1891–1899. doi:10.1158/1078-0432.CCR-13-283024691640
   PubMed Web of Science ®Google Scholar
• Correia de Sousa M, Gjorgjieva M, Dolicka D, et al. Deciphering miRNAs’ action through miRNA editing. Int J Mol Sci. 2019;20(24). doi:10.3390/ijms20246249
   PubMed Web of Science ®Google Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207. doi:10.1016/j.jaci.2017.08.03429074454
   PubMed Web of Science ®Google Scholar
• Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–333. doi:10.1038/nrc393225998712
   PubMed Web of Science ®Google Scholar
• Li J, Lu M, Jin J, et al. miR-449a suppresses tamoxifen resistance in human breast cancer cells by targeting ADAM22. Cell Physiol Biochem. 2018;50(1):136–149. doi:10.1159/00049396430278449
   PubMedGoogle Scholar
• Yang Y, Bao Y, Yang GK, et al. MiR-214 sensitizes human colon cancer cells to 5-FU by targeting Hsp27. Cell Mol Biol Lett. 2019;24:22. doi:10.1186/s11658-019-0143-330915129
   PubMed Web of Science ®Google Scholar
• Sun C, Wang FJ, Zhang HG, et al. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathway. World J Gastroenterol. 2017;23(10):1816–1827. doi:10.3748/wjg.v23.i10.181628348487
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7(6):454–465. doi:10.1038/nri209317525754
   PubMed Web of Science ®Google Scholar
• Singh S, Chouhan S, Mohammad N, et al. Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3. FEBS Lett. 2017;591(10):1371–1382. doi:10.1002/1873-3468.1265528417458
   PubMed Web of Science ®Google Scholar
• Chu Q, Shen D, He L, et al. Prognostic significance of SOCS3 and its biological function in colorectal cancer. Gene. 2017;627:114–122. doi:10.1016/j.gene.2017.06.01328603075
   PubMed Web of Science ®Google Scholar
• Hirahara K, Ghoreschi K, Yang XP, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity. 2012;36(6):1017–1030. doi:10.1016/j.immuni.2012.03.02422726954
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma CA, Lawrence MG, et al. PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients. J Exp Med. 2017;214(9):2523–2533. doi:10.1084/jem.2016142728710273
   PubMed Web of Science ®Google Scholar